Viral vector gene therapy is an innovative approach that utilizes engineered viruses to deliver therapeutic genes into patients’ cells, offering promising solutions for genetic disorders and chronic diseases. This industry features a range of companies dedicated to developing safe and effective gene therapies, with applications spanning from rare genetic conditions to widespread illnesses. An interesting trend shaping the sector is the growing focus on scalability and efficiency in vector production, as well as the integration of advanced technologies into therapeutic designs. As clinical research advances, the future looks bright for the improved treatment options that gene therapies can provide.

The companies featured in this article vary significantly in size, from start-ups to established organizations, and are primarily based in the United States, along with a growing presence in Europe and Asia. Most of these firms were founded in the last two decades and specialize in the development of gene therapy solutions, focusing on conditions like hemophilia, neurological disorders, and more. Their collective research and innovations are aimed at translates into viable treatments aimed at improving patient outcomes across the globe.

Continue reading to learn about the top viral vector gene therapy companies.

Top 23 Viral Vector Gene Therapy Companies

1. Spark Therapeutics, Inc.

• Website: sparktx.com
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing gene therapy treatments for genetic diseases. The company focuses on conditions such as hemophilia and inherited retinal diseases, aiming to provide innovative therapies that can transform patient care. Spark operates a fully integrated model that combines proprietary adeno-associated viral (AAV) gene therapy technology with robust research and development capabilities, as well as manufacturing operations. They have made significant strides in the field, including the development of Luxturna, the first approved gene therapy for a genetic disease in both the U.S. and EU. Spark's recent funding of $4.3 billion in 2019 highlights their financial backing and commitment to advancing gene therapy solutions. Their upcoming Gene Therapy Innovation Center is set to enhance their manufacturing capabilities and foster collaboration in the field, further solidifying their position in the industry.

2. AskBio Inc.

• Website: askbio.com
• Ownership type: Corporate
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 75%, United Kingdom (UK) 14%, France 6%, Other 5%
• Latest funding: $2.0B, October 2020
• Founded year: 2001
• Headcount: 501-1000
• LinkedIn: askbio

AskBio Inc., also known as Asklepios BioPharmaceutical, Inc., is a biotechnology company based in Durham, North Carolina, founded in 2001. The company is dedicated to developing innovative gene therapies for genetic diseases, utilizing advanced adeno-associated virus (AAV) technology. AskBio collaborates with researchers and healthcare providers to create life-saving therapies that address significant unmet medical needs across various genetic conditions. The company has a strong clinical pipeline, particularly in neuromuscular and central nervous system disorders, and has made notable advancements in gene therapy technology. In 2020, AskBio secured $2 billion in funding, which underscores its potential for growth and innovation in the field. The company also acquired Synpromics, enhancing its expertise in synthetic promoter technology, which is crucial for precise gene expression control in AAV therapies. AskBio's commitment to research and collaboration positions it as a significant player in the gene therapy industry.

3. Belief BioMed

• Website: beliefbiomed.com
• Ownership type: Private
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 100%
• Founded year: 2018
• Headcount: 201-500
• LinkedIn: belief-biomed

Belief BioMed Inc. is a Shanghai-based biotechnology firm founded in 2018, dedicated to the research, development, manufacturing, and clinical application of gene therapy products. The company focuses on creating innovative therapies for severe genetic and chronic diseases, leveraging advanced adeno-associated virus (AAV) vector technology. Belief BioMed has developed a comprehensive R&D pipeline targeting significant unmet medical needs, including conditions like hemophilia, Parkinson's disease, and neuromuscular disorders. Notably, their gene therapy product BBM-H901 for hemophilia B has received approval from the China National Medical Products Administration, marking a significant milestone as the first gene therapy for hemophilia in China. The company has also established a commercial production platform in China, enhancing its capabilities in vector manufacturing and clinical-grade production. With a commitment to making cutting-edge therapies accessible, Belief BioMed is actively contributing to the advancement of gene therapy in the healthcare sector.

4. NewBiologix

• Website: newbiologix.com
• Ownership type: Venture Capital
• Headquarters: Épalinges, Vaud, Switzerland
• Employee distribution: Switzerland 95%, United States (USA) 5%
• Latest funding: Series A, $50.3M, May 2023
• Founded year: 2023
• Headcount: 11-50
• LinkedIn: newbiologixsa

NewBiologix, founded in 2023 and based in Épalinges, Switzerland, is a biotechnology firm focused on gene therapy and cell therapy. The company is dedicated to developing innovative technologies for the production of viral vectors, which are essential for effective gene therapy treatments. Their proprietary HEK293 cell line is designed to enhance the safety and efficacy of AAV drugs, making treatments more accessible and affordable. NewBiologix aims to fill the innovation gap in the market by providing solutions for the large-scale production of viral vectors, addressing the growing demand for advanced therapy medicinal products (ATMPs) that target rare and chronic diseases. With a recent Series A funding round of approximately $50 million, NewBiologix is poised to expand its capabilities and partnerships in the biotechnology sector.

5. SIRION BIOTECH GmbH (Revvity Gene Delivery)

• Website: sirion-biotech.com
• Ownership type: Corporate
• Headquarters: Julbach, Bavaria, Germany
• Employee distribution: Germany 100%
• Latest funding: June 2021
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: sirion-biotech-gmbh

SIRION BIOTECH GmbH, based in Julbach, Bavaria, Germany, is a biotechnology firm founded in 2007. The company specializes in the development and manufacturing of viral vectors tailored for gene and cell therapy applications. SIRION serves a wide array of clients in the pharmaceutical and biotechnology sectors, providing high-quality viral vectors and transduction enhancers to support both research and therapeutic development. With a portfolio that includes AAV, lentivirus, and adenovirus technologies, SIRION has completed over 8000 projects, collaborating with more than 600 independent customers, including academic institutions and industry players. Their LentiBOOST transduction enhancer is currently involved in over 21 clinical trials, showcasing their active role in advancing gene therapy solutions. SIRION is committed to improving the clinical use of viral vectors, ensuring that their technologies meet the rigorous demands of the industry.

6. Jaguar Gene Therapy

• Website: jaguargenetherapy.com
• Ownership type: Venture Capital
• Headquarters: Lake Forest, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2022
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: jaguargenetherapy

Jaguar Gene Therapy, founded in 2019 and based in Lake Forest, Illinois, is a biotechnology firm dedicated to creating innovative gene therapies for severe genetic disorders. The company leverages advanced manufacturing processes and AAV-based delivery systems to develop safe and effective treatments. Their primary focus is on addressing the root causes of genetic diseases, with a pipeline that includes therapies for conditions such as galactosemia and severe neurodevelopmental disorders linked to the SHANK3 gene. Jaguar Gene Therapy collaborates with Advanced Medicine Partners to ensure high-quality manufacturing and product purity, which are critical for patient safety. The company is committed to accelerating the development timeline for gene therapies, aiming to provide timely solutions for patients and families affected by genetic disorders.

7. AnLong Bio

• Website: anlongbio.com
• Ownership type: Venture Capital
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Latest funding: Series A, January 2024
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: anlongbio

AnLong Bio, founded in 2019 and based in Beijing, China, is a biotechnology firm dedicated to the development of gene therapies for rare diseases. The company has established a strong network of clinical and manufacturing experts to support its mission of providing innovative and affordable treatments. AnLong Bio has developed platforms for adeno-associated virus (AAV) and RNA interference (RNAi), which are essential for their gene therapy initiatives. In 2023, they received approval for clinical trials of their AAV gene therapy product, AL-001, targeting age-related macular degeneration. This product reflects their focus on addressing significant clinical needs in the rare disease space. AnLong Bio has successfully raised funding, including a Series A round, which has enabled them to expand their clinical and manufacturing capabilities. Their strategic partnerships and commitment to innovation position them as a noteworthy player in the gene therapy sector.

8. Virovek, Inc.

• Website: virovek.com
• Ownership type: Private
• Headquarters: Houston, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: virovek-inc.

Virovek, Inc., founded in 2006 and based in Houston, Texas, is a biotechnology firm that specializes in gene therapy solutions. The company offers a range of products and services, including custom and pre-made adeno-associated virus (AAV) production, lentivirus packaging, and gene cloning. Virovek serves a clientele that includes academic institutions and organizations seeking advanced viral vectors for both research and therapeutic applications. They utilize proprietary technology to ensure high-quality and efficient production processes. Their BAC-to-AAV technology is noted for its capability to generate large-scale AAV production, which is critical for the development of gene therapies. Virovek's commitment to quality is reflected in their offerings of quality control assays and GLP manufacturing capabilities, further solidifying their role in the gene therapy industry.

9. FinVector Oy

• Website: finvector.com
• Ownership type: Private
• Headquarters: Kuopio, North Savo, Finland
• Employee distribution: Finland 99%
• Latest funding: Other (Debt), $48.2M, June 2023
• Founded year: 1993
• Headcount: 201-500
• LinkedIn: finvector-vision-therapies-oy

FinVector Oy, based in Kuopio, Finland, is a biopharmaceutical company that specializes in the manufacturing of viral-based gene therapy products. Founded in 1993, the company has built a reputation for its commitment to improving the lives of patients with chronic health conditions, particularly bladder cancer. FinVector operates a modern cGMP manufacturing facility that adheres to stringent regulatory standards, ensuring the safety and efficacy of its products. The company has recently gained attention for its collaboration with Ferring Pharmaceuticals, producing the viral vector-based drug substance for the FDA-approved gene therapy Adstiladrin®. This partnership underscores FinVector's role in the global gene therapy market. In June 2023, the company secured significant funding, which will likely enhance its manufacturing capabilities and support ongoing research and development efforts. With a workforce of over 500 professionals, FinVector is positioned as a key player in the biopharmaceutical sector, dedicated to advancing gene therapy solutions.

10. Carbon Biosciences

• Website: carbonbio.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $38.0M, June 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: c12bio

Carbon Biosciences, founded in 2021 and based in Boston, Massachusetts, is a biotechnology firm dedicated to advancing gene therapy and genetic medicines. The company aims to create innovative treatments for genetic diseases by harnessing the power of natural viral evolution. Their proprietary CBN vector library is designed to offer advantages such as enhanced tissue specificity and the ability to carry larger genetic payloads. Carbon Biosciences has attracted significant investment, securing $38 million in a Series A funding round in June 2022, which underscores their potential in the gene therapy market. Their primary customers include healthcare providers and pharmaceutical companies seeking cutting-edge therapeutic solutions. The company is actively working on developing gene therapies, including a candidate targeting cystic fibrosis, showcasing their commitment to addressing serious health challenges.

11. Amarna Therapeutics

• Website: amarnatherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Leiden, South Holland, Netherlands
• Employee distribution: Netherlands 88%, Spain 12%
• Latest funding: Other (Grant), January 2022
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: amarna-therapeutics-b.v.

Amarna Therapeutics is a biotechnology firm based in Leiden, South Holland, Netherlands, founded in 2008. The company specializes in gene therapy, leveraging its proprietary Nimvec™ platform to develop innovative treatments for a range of diseases, including Type 1 Diabetes, Hemophilia A and B, obesity, multiple sclerosis, and age-related macular degeneration. With a small team of 11-50 employees, Amarna Therapeutics is focused on creating transformative therapies that aim to provide potentially curative solutions for patients. The company has received grants for its research and development efforts, indicating support for its innovative approaches. Their recent interactions with regulatory bodies, such as the FDA, highlight their active participation in the gene therapy landscape and their commitment to advancing their therapeutic pipeline.

12. AAVantgarde Bio

• Website: aavantgarde.com
• Ownership type: Venture Capital
• Headquarters: Milan, Lombardy, Italy
• Employee distribution: United Kingdom (UK) 49%, Italy 44%, Switzerland 7%
• Latest funding: Series A, $65.3M, June 2023
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: aavantgarde-bio

AAVantgarde Bio is a clinical-stage biotechnology company based in Milan, Italy, founded in 2021. The company specializes in gene therapy, particularly through the use of adeno-associated viral (AAV) vectors. AAVantgarde has developed two proprietary platforms aimed at overcoming the limitations of traditional AAV vectors, specifically their small DNA cargo capacity. This innovation is crucial for delivering larger genes, which is particularly relevant for treating inherited retinal diseases. The company is currently validating its platforms in clinical trials for Usher syndrome type 1B and Stargardt disease, both of which represent significant unmet medical needs. AAVantgarde has attracted substantial investment, including a €61 million Series A financing round in June 2023, indicating strong support for its mission to broaden the application of AAV-based therapies. The company originated from research at the Telethon Institute of Genetics and Medicine (TIGEM) and is co-founded by Professor Alberto Auricchio, a recognized figure in the field of gene therapy. AAVantgarde aims to deliver next-generation genetic medicines to underserved patient populations, reflecting its commitment to addressing critical health challenges.

13. Andelyn Biosciences

• Website: andelynbio.com
• Ownership type: Private
• Headquarters: Columbus, Ohio, United States (USA)
• Employee distribution: United States (USA) 99%
• Latest funding: Other (Grant), $5.0M, February 2022
• Founded year: 2020
• Headcount: 201-500
• LinkedIn: andelyn-biosciences

Andelyn Biosciences, founded in 2020 and based in Columbus, Ohio, is a private biotechnology firm focused on gene therapy and viral vector manufacturing. The company offers a range of services that facilitate the transition from research to scalable manufacturing for biotechnology and pharmaceutical clients. Their capabilities include process development, analytical testing, and quality control, all designed to meet stringent regulatory standards. With a workforce of approximately 232 employees, Andelyn has established itself as a reliable contract development and manufacturing organization (CDMO) in the gene therapy space. The company has been involved in the production of over 450 cGMP clinical batches and has supported more than 75 INDs, showcasing their commitment to advancing gene therapies for rare diseases. In 2022, they secured $5 million in funding, further solidifying their position in the market.

14. Affinia Therapeutics

• Website: affiniatx.com
• Ownership type: Private Equity
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $110.0M, May 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: touchdown-therapeutics

Affinia Therapeutics, founded in 2019 and based in Waltham, Massachusetts, is a biotechnology company dedicated to advancing gene therapy solutions. The firm focuses on developing targeted treatments for genetic diseases, particularly those impacting the heart and nervous system. Utilizing their proprietary ART (Affinia Rationally-designed Therapies) platform, Affinia employs advanced techniques such as AI and structural modeling to create more effective gene therapies. Their work is centered around improving the delivery mechanisms of adeno-associated viruses (AAV), which are crucial for the success of gene therapies. Affinia has garnered significant financial backing, with a Series B funding round raising $110 million in May 2021, reflecting strong investor interest in their innovative approach to gene therapy.

15. Forge Biologics

• Website: forgebiologics.com
• Ownership type: Corporate
• Headquarters: Columbus, Ohio, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: $620.0M, November 2023
• Founded year: 2020
• Headcount: 201-500
• LinkedIn: forge-biologics

Forge Biologics, founded in 2020 and based in Columbus, Ohio, is a biotechnology company focused on the development and manufacturing of gene therapies. The company specializes in AAV gene therapies and plasmid DNA, providing comprehensive manufacturing solutions that support pharmaceutical and biotech companies in bringing innovative treatments to market. Their operations are conducted in a state-of-the-art, cGMP compliant facility, ensuring adherence to the highest production standards. Forge Biologics is also developing its own pipeline of gene therapies, including FBX-101, aimed at treating Krabbe Disease. With a recent funding round of $620 million in November 2023, the company is well-positioned to accelerate its growth and enhance its capabilities in the gene therapy space.

16. Replay

• Website: replay.bio
• Ownership type: Private Equity
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 94%, United Kingdom (UK) 6%
• Latest funding: Series A, $55.0M, July 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: replay-holdings-llc

Replay is a biotechnology firm based in San Diego, California, founded in 2021. The company focuses on genomic medicine, specifically developing innovative gene therapies using high payload herpes simplex virus (HSV) delivery systems. Their technology, known as synHSV™, enables the delivery of large genetic constructs, which is crucial for addressing complex genetic diseases. Replay operates through a hub-and-spoke model, allowing for the separation of technology development from therapeutic product development. They have launched product companies such as Telaria, which targets rare skin diseases, and Eudora, focused on retinal diseases. In July 2022, Replay secured $55 million in Series A funding, indicating strong investor confidence in their approach to tackling significant medical challenges. With a dedicated team of experts and a clear focus on unmet medical needs, Replay is positioned to make impactful contributions to the field of gene therapy.

17. Capsida Biotherapeutics

• Website: capsida.com
• Ownership type: Venture Capital
• Headquarters: Thousand Oaks, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: February 2023
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: capsida-biotherapeutics

Capsida Biotherapeutics, based in Thousand Oaks, California, is a biotechnology company that specializes in gene therapy. Founded in 2019, Capsida is dedicated to creating targeted, non-invasive therapies for serious conditions, including genetic epilepsy and Parkinson's disease. The company utilizes advanced capsid engineering techniques to enhance the delivery of gene therapies, achieving significant neuronal transduction while minimizing exposure to non-target organs. Capsida's pipeline includes several promising programs focused on the central nervous system (CNS) and serious eye diseases, supported by strategic partnerships with industry leaders like AbbVie and CRISPR Therapeutics. Their fully integrated platform encompasses all aspects of gene therapy development, from research and development to clinical trials, positioning them as a notable entity in the gene therapy industry.

18. Exegenesis Bio

• Website: exegenesisbio.com
• Ownership type: Private Equity
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: China 65%, United States (USA) 35%
• Latest funding: Series B, February 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: exegenesis

Exegenesis Bio is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2019. The company focuses on developing innovative gene and cell therapies, particularly targeting diseases such as Spinal Muscular Atrophy, Parkinson's Disease, and Wet Age-related Macular Degeneration. With a strong emphasis on research and development, Exegenesis Bio aims to create advanced treatment options for patients worldwide. The company has established a robust pipeline of gene therapies and possesses integrated manufacturing capabilities, which are crucial for the production of viral vector therapies. Exegenesis Bio has raised over $120 million in funding, indicating strong financial backing and support for its ambitious goals in the gene therapy space. Their proprietary platforms, including AAVarta® for AAV capsid design and Constellation® for gene expression cassette design, showcase their commitment to innovation in the field.

19. Dyno Therapeutics

• Website: dynotx.com
• Ownership type: Venture Capital
• Headquarters: Watertown, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $100.0M, May 2021
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: dynotx

Dyno Therapeutics is a biotechnology firm based in Watertown, Massachusetts, founded in 2018. The company is dedicated to revolutionizing gene therapy through the application of artificial intelligence to develop optimized adeno-associated virus (AAV) vectors. These vectors are essential for delivering gene therapies effectively to target cells. Dyno's CapsidMap™ platform allows for the systematic design and testing of AAV capsids, addressing limitations of naturally occurring vectors. Their product offerings include the Dyno bCap 1 and eCap 1 capsids, which have shown significant improvements in transduction efficiency in preclinical studies. Dyno has secured substantial funding, including a $100 million Series A round led by Andreessen Horowitz, which underscores the potential of their technology. The company collaborates with major pharmaceutical firms, enhancing their capabilities in gene therapy applications across various diseases.

20. American Gene Technologies International Inc.

• Website: americangene.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, April 2022
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: american-gene-technologies-international-inc

American Gene Technologies International Inc. (AGT) is a biotechnology firm based in Rockville, Maryland, founded in 2007. The company is dedicated to developing innovative gene therapies aimed at treating serious health conditions, including infectious diseases like HIV, genetic disorders such as Phenylketonuria (PKU), and various cancers. AGT utilizes a proprietary lentiviral vector platform, which allows for the targeted delivery of genetic material into cells. This technology is central to their therapeutic strategies, enabling them to create long-lasting treatments. AGT has been involved in multiple clinical trials, with their HIV cure program showing promising results in early phases. The company has also established collaborations with medical researchers to enhance their research capabilities and expedite the development of their therapies. AGT's commitment to advancing gene therapy is evident in their ongoing projects and the establishment of a new company, Addimmune, to further focus on HIV cure development.

21. Regel Therapeutics

• Website: regeltherapeutics.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $1.0M, September 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: regel-therapeutics

Regel Therapeutics, founded in 2020 and based in Boston, Massachusetts, is a private biotechnology company dedicated to advancing targeted gene therapy for severe genetic disorders. The company leverages its proprietary T3 platform, which combines AAV delivery with a programmable dCas system to correct abnormal gene expression specifically in affected cells. This innovative approach aims to provide effective therapeutic solutions for patients suffering from genetic diseases, particularly those that have been difficult to treat. Regel's pipeline includes programs targeting Dravet syndrome and SCN2A haploinsufficiency, both of which are associated with significant patient challenges and limited current treatment options. In September 2023, Regel Therapeutics secured $1 million in funding through a grant, indicating ongoing support for their research and development efforts in the biotechnology sector.

22. Ring Therapeutics

• Website: ringtx.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $86.5M, March 2023
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: ring-therapeutics

Ring Therapeutics, founded in 2017 and based in Cambridge, Massachusetts, is a biotechnology company dedicated to advancing programmable genetic medicines. The firm specializes in harnessing the human commensal virome, particularly through their proprietary Anellovector and AnelloLP platforms, to create therapies that can effectively target various diseases. Their innovative approach leverages the unique properties of anelloviruses, which are naturally present in humans and can evade the immune system, making them promising candidates for gene delivery. Ring Therapeutics primarily serves healthcare providers and researchers, aiming to provide advanced treatment options for conditions with significant unmet needs. The company has recently secured $86.5 million in Series C funding, reflecting strong investor interest in their pioneering work in the field of gene therapy.

23. Ascend Advanced Therapies

• Website: ascend-adv.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 45%, Germany 43%, United Kingdom (UK) 12%
• Latest funding: $130.6M, November 2024
• Founded year: 2022
• Headcount: 51-200
• LinkedIn: ascend-gene-cell-therapies

Ascend Advanced Therapies is a biotechnology firm based in Rockville, Maryland, established in 2022. The company specializes in the development and manufacturing of gene therapies utilizing adeno-associated viruses (AAVs). Ascend offers a comprehensive suite of services, including AAV vector design, quality assurance, and analytical capabilities, aimed at assisting biotech and pharmaceutical companies in navigating the complexities of bringing new therapies to market. With a workforce of approximately 166 employees, Ascend operates facilities in the USA, Germany, and the UK, reflecting a strong international presence. The company has recently secured over $130 million in funding, which underscores its potential for growth and innovation in the gene therapy space. Ascend's mission is to create effective, high-quality, and scalable gene therapies, making them a vital partner for organizations looking to advance their therapeutic products from preclinical stages through to commercialization.

Viral Vector Gene Therapy Insights: Key Companies

Want to Find More Viral Vector Gene Therapy Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!